Phase 2b Controlled Trial of M72/AS01 E Vaccine to Prevent Tuberculosis
New England Journal of Medicine2018Vol. 379(17), pp. 1621–1634
Citations Over TimeTop 1% of 2018 papers
Olivier Van Der Meeren, Mark Hatherill, Videlis Nduba, Robert J. Wilkinson, Monde Muyoyeta, Elana van Brakel, Helen Ayles, Germán Henostroza, Friedrich Thienemann, Thomas J. Scriba, Andreas H. Diacon, Gretta Blatner, Marie‐Ange Demoitié, Michèle Tameris, Mookho Malahleha, James C. Innes, Elizabeth Hellström, Neil Martinson, Tina Singh, Elaine Jacqueline Akité, Aisha Azam, Anne Bollaerts, Ann M. Ginsberg, Thomas G. Evans, Paul Gillard, Dereck Tait
Abstract
M72/AS01E provided 54.0% protection for M. tuberculosis-infected adults against active pulmonary tuberculosis disease, without evident safety concerns. (Funded by GlaxoSmithKline Biologicals and Aeras; ClinicalTrials.gov number, NCT01755598 .).
Related Papers
- → A comparison of placebo effects in clinical analgesic trials versus studies of placebo analgesia(2002)434 cited
- → Altered Placebo and Drug Labeling Changes the Outcome of Episodic Migraine Attacks(2014)391 cited
- → Conditioned Placebo Analgesia Persists When Subjects Know They Are Receiving a Placebo(2015)116 cited
- → Μελέτη της πολυπαραγοντικής αναλγησίας στο μετεγχειρητικό πόνο μετά από λαπαροσκοπική χολοκυστεκτομή(2014)
- → Ιστορική εξέλιξη της έννοιας του placebo από τα μέσα του 19ου αιώνα μέχρι σήμερα(2006)